

Serial No.: 09/500,376
Filing Date: February 8, 2000

AMENDMENT

In The Claims

Please amend claims 37, 41, 42, 50 and 54 as follows:

37. A pharmaceutical composition for treating plasmodium parasitemia in a mammal, said composition comprising:

D1
an isolated p42 polypeptide comprising at least a portion of the 42 kDa C-terminal processing fragment of major merozoite surface protein gp195 from a *Plasmodium falciparum* isolate, wherein said isolated p42 polypeptide shares at least one antigenic epitope with a polypeptide according to any one of SEQ.ID NOs. 2-5, in combination with an adjuvant selected from the group consisting of QS-21 and ISA51 and mixtures thereof.

D2
41. The pharmaceutical composition of Claim 37, wherein said isolated p42 polypeptide is a native sequence p42 polypeptide.

42. The pharmaceutical composition of Claim 37, wherein said p42 polypeptide comprises SEQ. ID No. 8.

D3
50. An anti-plasmodium vaccine comprising an immunogenic amount of an isolated p42 polypeptide comprising at least a portion of the C-terminal processing fragment of major merozoite surface protein gp195 from a *Plasmodium falciparum* isolate, wherein said isolated p42 polypeptide shares at least one antigenic epitope with a polypeptide according to any one of SEQ.ID NOs. 2-5, said p42 polypeptide being expressed by an insect cell which contains a vector that encodes said polypeptide, in combination with an adjuvant selected from the group consisting of QS21 and ISA51 and mixtures thereof,

wherein said isolated p42 polypeptide is more immunogenic in a mammalian host than is the same polypeptide expressed in yeast.

D4
54. The method of Claim 53, wherein said immune response provides at least 92% inhibition of plasmodium parasitemia in said mammal.